TY - JOUR
T1 - Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity.
AU - van Acker, S.A.B.E.
AU - Kramer, K.
AU - Grimbergen, J.A.
AU - van den Berg, D.J.
AU - van der Vijgh, W.J.F.
AU - Bast, A.
PY - 1995
Y1 - 1995
N2 - The clinical use of the antitumour agent, doxorubicin, is largely limited by the development of a cumulative dose‐related cardiotoxicity. This toxicity is generally believed to be caused by the formation of oxygen free radicals. In earlier studies it was established that flavonoids, naturally occurring antioxidants, can provide some degree of protection. In this study we investigated whether 7‐monohydroxyethylrutoside (monoHER), a powerful antioxidative flavonoid with extremely low toxicity, can provide protection to an extent comparable to the clinically successful Cardioxane (ICRF‐187). Balb/c mice of 20–25 g were equipped i.p. with a telemeter to measure ECG. They were given 6 i.v. doses of doxorubicin (4 mg kg
AB - The clinical use of the antitumour agent, doxorubicin, is largely limited by the development of a cumulative dose‐related cardiotoxicity. This toxicity is generally believed to be caused by the formation of oxygen free radicals. In earlier studies it was established that flavonoids, naturally occurring antioxidants, can provide some degree of protection. In this study we investigated whether 7‐monohydroxyethylrutoside (monoHER), a powerful antioxidative flavonoid with extremely low toxicity, can provide protection to an extent comparable to the clinically successful Cardioxane (ICRF‐187). Balb/c mice of 20–25 g were equipped i.p. with a telemeter to measure ECG. They were given 6 i.v. doses of doxorubicin (4 mg kg
U2 - 10.1111/j.1476-5381.1995.tb15034.x
DO - 10.1111/j.1476-5381.1995.tb15034.x
M3 - Article
VL - 115
SP - 1260
EP - 1264
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
SN - 0007-1188
ER -
